Literature DB >> 26888800

Effectiveness of platelet inhibition on major adverse cardiac events in non-cardiac surgery after percutaneous coronary intervention: a prospective cohort study.

M Wąsowicz1, S Syed2, D N Wijeysundera3, Ł Starzyk4, D Grewal4, T Ragoonanan4, P Harsha2, G Travis2, J Carroll4, K Karkouti5, W S Beattie6.   

Abstract

BACKGROUND: Platelet inhibition is mandatory therapy after percutaneous coronary intervention (PCI). Withdrawal of oral antiplatelet agents has been linked to increased incidence of postoperative adverse cardiac events in post-PCI patients having non-cardiac surgery (NCS). There is limited knowledge of temporal changes in platelet inhibition in this high-risk surgical population. We therefore performed a multicentre prospective cohort study evaluating perioperative platelet function and its association with postoperative major adverse cardiac events (MACE).
METHODS: In 201 post-PCI patients having NCS, we assessed the association between platelet function and postoperative MACE. We performed perioperative platelet function testing using a platelet mapping assay (PMA). Troponin-I was measured every 8 h for 2 days, then daily until day 5. Myocardial infarction was assessed using the third universal definition. We used multivariable logistic regression to assess the association between platelet inhibition and MACE.
RESULTS: Major adverse cardiac events occurred in 40 patients within 30 days of surgery. Thirty-two of these events were non-ST-elevation myocardial infarction, four ST-elevation myocardial infarction, and four exacerbation of congestive heart failure. We were unable to show an association between platelet inhibition and MACE. The PMA showed declining levels of platelet inhibition the longer the antiplatelet therapy was withheld before surgery. Logistic regression did not show an association between preoperative platelet function or the type of stent and MACE. We found an increased cardiac risk of MACE after surgery within 6 weeks of PCI.
CONCLUSIONS: The incidence of MACE in patients undergoing NCS after previous PCI is high in spite of adequate perioperative antiplatelet therapy. CLINICAL TRIAL REGISTRATION: NCT 01707459 (registered at http://www.clinicaltrials.gov).
© The Author 2016. Published by Oxford University Press on behalf of the British Journal of Anaesthesia. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  major adverse cardiac events; non-cardiac surgery; percutaneous coronary intervention; platelet inhibition

Mesh:

Substances:

Year:  2016        PMID: 26888800     DOI: 10.1093/bja/aev556

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  4 in total

1.  Association between intraoperative hypotension and postoperative myocardial injury in patients with prior coronary stents undergoing high-risk surgery: a retrospective study.

Authors:  Sang Hyun Lee; Jie Ae Kim; BurnYoung Heo; Young Ri Kim; Hyun Joo Ahn; Mikyung Yang; Jaeni Jang; Soohyun Ahn
Journal:  J Anesth       Date:  2020-01-21       Impact factor: 2.078

2.  Association Between Antifibrinolytic Therapy and Perioperative Outcomes in Patients With Coronary Artery Stents Undergoing Noncardiac Surgery.

Authors:  Michael R Boswell; Mark M Smith; Ryan D Frank; Michael J Brown; Arnoley S Abcejo; Todd M Kor; Rajiv Gulati; Bradford B Smith
Journal:  Anesth Analg       Date:  2021-06-01       Impact factor: 6.627

3.  Risk of non-cardiac surgery after percutaneous coronary intervention with drug-eluting stents.

Authors:  Sun-Kyung Park; Dhong Eun Jung; Sung Ae Jung; Won Ho Kim; Jae-Hyon Bahk
Journal:  Sci Rep       Date:  2017-11-27       Impact factor: 4.379

Review 4.  Continuation versus discontinuation of antiplatelet therapy for bleeding and ischaemic events in adults undergoing non-cardiac surgery.

Authors:  Sharon R Lewis; Michael W Pritchard; Oliver J Schofield-Robinson; Phil Alderson; Andrew F Smith
Journal:  Cochrane Database Syst Rev       Date:  2018-07-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.